Application of farnesoid X receptor agonists in treatment of nonalcoholic steatohepatitis
10.3969/j.issn.1001-5256.2022.06.038
- VernacularTitle:法尼醇X受体激动剂在非酒精性脂肪性肝炎治疗中的应用
- Author:
Zhenyang SHEN
1
;
Xiaobo CAI
1
;
Lungen LU
1
Author Information
1. Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
- Publication Type:Reviews
- Keywords:
Non-alcoholic Steatohepatitis;
Farnesoid X Receptor;
Drug Therapy
- From:
Journal of Clinical Hepatology
2022;38(6):1402-1405
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic steatohepatitis (NASH) is a liver disease with a relatively high prevalence worldwide and greatly threatens human health. In recent years, farnesoid X receptor-related drugs have played an important role in regulating the metabolism of bile acid, glucose, and lipids and inhibiting inflammation. This article summarizes the application of farnesoid X receptor agonists in the treatment of NASH, so as to provide a basis for the prevention and treatment of NASH.
